Columbus Macro LLC Takes Position in Humana Inc. (NYSE:HUM)

Columbus Macro LLC bought a new position in Humana Inc. (NYSE:HUM) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 877 shares of the insurance provider’s stock, valued at approximately $223,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Creative Financial Designs Inc. ADV boosted its position in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares during the period. Atwood & Palmer Inc. purchased a new stake in shares of Humana in the third quarter worth approximately $29,000. Ashton Thomas Securities LLC acquired a new stake in shares of Humana during the third quarter worth approximately $31,000. Your Advocates Ltd. LLP grew its position in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. Finally, LRI Investments LLC increased its stake in Humana by 1,021.4% in the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after buying an additional 143 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Up 0.9 %

HUM opened at $295.68 on Wednesday. The business has a 50 day moving average of $275.13 and a 200-day moving average of $300.37. The stock has a market capitalization of $35.60 billion, a price-to-earnings ratio of 26.19, a P/E/G ratio of 2.21 and a beta of 0.56. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46.

Insider Buying and Selling at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HUM. Royal Bank of Canada decreased their target price on shares of Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Wells Fargo & Company dropped their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. KeyCorp began coverage on Humana in a report on Friday, October 11th. They set a “sector weight” rating for the company. Stephens restated an “equal weight” rating and issued a $250.00 price objective on shares of Humana in a report on Wednesday, October 9th. Finally, Piper Sandler lifted their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.